Regulatory News
Monday, November 21, 2016
BRIEF-CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting
* CTi Biopharma announces phase 3 data from the PERSIST-2
trial of Pacritinib to be presented in late-breaking session at
ASH annual meeting
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment